IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC
type: MedicalStudy
description: The Phase Ib/II, Open-label, Multicenter Study of IBI310 (Anti-CTLA4 mAb) in Combination With Sintilimab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma That Failed Prior Anti-PD-1/PD-L1 Therapy
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE1
start date: 2021-07-23
end date: 2023-02-06
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT04945421
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Innovent Biologics (Suzhou) Co. Ltd.
study subject: NPC
keywords: PHASE1
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: NPC

AI Analytics
type: Organization